Search

Your search keyword '"Louis Lacombe"' showing total 303 results

Search Constraints

Start Over You searched for: Author "Louis Lacombe" Remove constraint Author: "Louis Lacombe"
303 results on '"Louis Lacombe"'

Search Results

1. A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation

2. Regulatory and memory T lymphocytes infiltrating prostate tumors predict long term clinical outcomes

3. Effects of omega‐3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double‐blind placebo‐controlled randomized trial

4. Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic–mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer

5. High infiltration of CD209+ dendritic cells and CD163+ macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes

6. Double inferior vena cava systems during retroperitoneal surgery: Description of a systematic approach to a rare and challenging anatomic variant

7. Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer

8. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

9. Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion

10. Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA)

11. Discordance between testosterone measurement methods in castrated prostate cancer patients

12. Uridine Diphosphate Glucuronosyl Transferase 2B28 (UGT2B28) Promotes Tumor Progression and Is Elevated in African American Prostate Cancer Patients

13. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation

14. Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.

15. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

16. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

17. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

18. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

19. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

20. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

21. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

22. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

23. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

24. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

25. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

26. Cystatin C for early detection of acute kidney injury after laparoscopic partial nephrectomy

27. Complete Penile Necrosis in a Patient With Heparin-induced Thrombocytopenia: A Case Report

29. Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer

30. Table S2 from Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non–Muscle-Invasive Bladder Cancer: A Gene–Smoking Interaction

31. Supplementary Figure Legends from Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer

32. Supplementary Figures S3 to S6 from Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer

33. Data from Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer

34. Supplementary Tables S1 and S2 from Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer

35. Supplementary Figure S2 from Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer

36. Data from Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non–Muscle-Invasive Bladder Cancer: A Gene–Smoking Interaction

37. Supplementary Tables 1 - 4 from Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression

38. Data from Importance of 5α-Reductase Gene Polymorphisms on Circulating and Intraprostatic Androgens in Prostate Cancer

39. Supplementary Tables 1 - 7 from Steroidogenic Germline Polymorphism Predictors of Prostate Cancer Progression in the Estradiol Pathway

40. Data from Steroidogenic Germline Polymorphism Predictors of Prostate Cancer Progression in the Estradiol Pathway

42. Data from Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression

43. Supplemental Figure Legends from CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy

45. Supplemental Figure 3 from CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy

47. Data from CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy

48. Supplemental Figure 5 from CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy

Catalog

Books, media, physical & digital resources